- Home
- PRCT vs CTY Comparison
PRCT vs CTY Comparison
Compare PRCT & CTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRCT | CTY |
|---|---|---|
| Founded | 2009 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2021 | 2026 |
Fundamental Metrics
Financial Performance| Metric | PRCT | CTY |
|---|---|---|
| Price | $23.99 | $17.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 3 |
| Target Price | $22.75 | ★ $37.33 |
| AVG Volume (30 Days) | ★ 1.2M | 238.1K |
| Earning Date | 11-04-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $308,054,000.00 | N/A |
| Revenue This Year | $28.44 | $62.96 |
| Revenue Next Year | $20.02 | $7.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.22 | N/A |
| 52 Week Low | $16.67 | $15.81 |
| 52 Week High | $38.11 | $22.65 |
Technical Indicators
Market Signals| Indicator | PRCT | CTY |
|---|---|---|
| Relative Strength Index (RSI) | 68.71 | 39.86 |
| Support Level | $20.22 | $16.01 |
| Resistance Level | $26.41 | $21.98 |
| Average True Range (ATR) | 1.41 | 2.22 |
| MACD | 0.40 | -0.20 |
| Stochastic Oscillator | 92.41 | 23.83 |
Price Performance
Historical ComparisonAbout PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
About CTY City Therapeutics Inc. Common Stock
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.